Business Context and Reporting Period
This Form 8-K Current Report was filed by Corvus Pharmaceuticals, Inc. on October 2, 2025. The filing discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Board Retainer: $35,000
- Compensation Committee Fee: $6,000 annually
- Nominating Committee Fee: $4,000 annually
- Initial Equity Grant: Stock option to purchase 30,000 shares of Common Stock
Material Changes
On October 2, 2025, the Board of Directors appointed David Moore as a Class III director. His term expires at the 2028 annual meeting of stockholders. Mr. Moore was simultaneously appointed to the Compensation Committee and the Nominating Committee, effective immediately.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details the appointment and compensatory arrangements for the new director, referencing the Company's non-employee director compensation program and standard indemnification agreement filed in the March 25, 2025 Form 10-K.
Investor Verification Checklist
- Verify the independence status of the newly appointed director, David Moore.
- Review the Company's 2016 Equity Incentive Award Plan to understand the terms of the 30,000-share option grant.
- Confirm the total number of authorized shares remaining in the equity plan following this grant.
- Check the Company's most recent Form 10-K (filed March 25, 2025) for the full text of the director compensation program and indemnification agreement.